-
The Lancet: What's new! The loss of 382 nucleotides may make SARS-CoV-2 infections milder!
Time of Update: 2020-10-06
In a study by 2 genome on the severity of infection and the appy response: an observational cohort study, scientists from institutions such as the Singapore Science and Technology Research Agency (A-STAR) found genetic mutations that make the SARS-CoV-2 virus mild.
-
Cell: Study reveals why immunotherapy causes neurotoxicity.
Time of Update: 2020-10-06
Our study shows that CD19 expression is present in some non-B cells, which may be related to neurotoxicity that we observed in patients treated with CD19-targeted CAR T cell therapy," said Posey.
Single-Cell Analytics Identify Brain Mural Cells ExpressING CD19 as Off Potential-Tumor Targets for CAR-T Immunotherapies.
-
Front Immunol: Male COVID19 patients had a higher mortality rate.
Time of Update: 2020-10-06
a review published in Frontiers in Immunology, BIDMC researchers-clinicians looked at gender-based physiological differences that may affect the risk and susceptivity of COVID-19, the course and clinical outcomes of the disease, and the response to vaccines.
-
Cancer Res: Incredible! Increased growth hormone levels may increase the body's risk of multiple cancers!
Time of Update: 2020-10-06
September 18, 2020 // -- In a recent study published in the international journal Lancer Research, scientists from Oxford University and others studied nearly 400,000 people in the UK and found a link
-
Cell overview compilation in full! It is pointed out that the new coronavirus may inhibit the long-acting antibody response, but it is still possible to achieve immune memory through virus-specific memory T cells.
Time of Update: 2020-10-06
Based on these results, it is easy to speculate that while the optimal protective immunity induced by COVID-19 infection may depend on the production of memory T cells and long-lived plasma cells originating from the birth center, any single reaction may be somewhat immune to serious diseases.
-
The study revealed the molecular mechanism of soybean-subject kinase as a molecular switch to regulate disease-resistant immune triggers.
Time of Update: 2020-10-06
GmLMM1 functionally missing mutants show cell death, PTI activation and reactive oxygen accumulation, enhanced ideotype resistance to bacterial and ovary pathogens, and after flog22 treatment, ROS bursts increased significantly, triggering an immune response to disease.
-
Science: Long-term infection with the new coronavirus has an effect on the long-term effective response of the immune system.
Time of Update: 2020-10-06
September 23, 2020 /---Xinhua) -- Natural immunization and vaccine-induced immunity will be key factors affecting the future trajectory of the global coronavirus pandemic (COVID-19), according to new research.
-
Cell: Animal studies have found that small antibodies are effective in treating and preventing new coronavirus infections.
Time of Update: 2020-10-06
, co-author of the study and director of the Infectious Diseases Section at the University of Pittsburgh School of Medicine, said, "Ab8 not only has the potential to treat COVID-19, but may also be used to prevent people from contracting SARS-CoV-2.
-
Nat Genet: Genetic mutations associated with immune cells may affect an individual's risk of developing autoimmune diseases.
Time of Update: 2020-10-06
In the study, researchers studied blood samples from 3,500 participants in sardinia, Italy, using genotype spectrometry and attribution analysis as a means of finding mutations involving 731 immune cell properties, including the use of cell surface markers and cell segments based on fluid cytometry.
-
Stem Cells: Scientists in China have revealed that genetically modified human erypotent stem cells evade immune system recognition, laying the groundwork for a common 'off-the-go' cell transplant.
Time of Update: 2020-10-06
results were published online September 15, 2020 in the journal Stem Cells under the title "Generation of hypomunogenic human pluripotent stem cells via expression of the mail-bound and secreted beta-2m-HLA-G fusions." and Lin Ma of Tongji University School of Medicine.
-
Eli Lilly and Amgen reach cooperation on COVID-19 antibody therapy
Time of Update: 2020-10-06
a single injection of its experimental antibody, LY-CoV-555, could reduce hospitalization and emergency visits for patients in clinical trials with moderate C0VID-19, according to data from an interim trial released Wednesday by Lilly.
-
Plos Med: Are rheumatoid arthritis two different diseases?
Time of Update: 2020-10-06
SEPTEMBER 24, 2020 /--- According to a new study published this week in THE journal PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center in the Netherlands, while the activity of most rheumatoid arthritis (RA) patients improves over time, long-term results only improve RA patients' own antibodies.
-
Journal of Science: Children's immune response is effective against COVID-19.
Time of Update: 2020-10-06
"Our findings suggest that children with COVID-19 perform better than adults because their strong innology immunity protects them from SARS-CoV-2 infections," said Betsy Herold, M.D., co-senior author of the study and head of infectious diseases.
-
The first JAK inhibitor to treat adiotic dermatitis (AD)! Lilly Olumiant's new adaptation is recommended for approval by THECHMP!
Time of Update: 2020-10-06
September 20, 2020 // -- Eli Lilly and partner Incyte recently announced that the European Medicines Agency (EMA) Committee on Human Pharmaceutical Products (CHMP) has issued an active review recommending approval of oral JAK inhibitor Olumiant (baricitinib) for the treatment of moderate to severe endexual dermatitis (AD) patients suitable for systematic treatment.
-
How to use special small molecules to enhance the function of the host's own immune system to resist the occurrence of a variety of infectious diseases?
Time of Update: 2020-10-06
September 23, 2020 // -- Infections pose a significant health risk to hospitalized patients, and recently, scientists from institutions such as the Fraunhofer Institute of Interface Engineering and Bi
-
Cell: Reveals that T cells play a leading role in controlling SARS-CoV-2 and reducing the severity of COVID-19.
Time of Update: 2020-10-06
, co-author of the paper and professor at the Center for Infectious Diseases and Vaccines at the La Hoya Institute of Immunology, said, "Our observations may also explain why older COVID-19 patients are more susceptible to the disease." As we age, the T-cell pool that can be activated by a particular virus decreases and the body's immune response becomes less coordinated, which appears to be a factor that makes older people particularly vulnerable to severe or fatal COVID-19 effects.
-
New Crown Outbreak: 30.33 million! Lilly and Amjin strong joint: production and antibody supply worldwide, prevention and treatment COVID-19!
Time of Update: 2020-10-06
sars-CoV-2 spread rapidly among residents of long-term care facilities, coupled with high mortality rates among older people, there is an urgent need for treatment to prevent COVID-19 in this vulnerable population.
-
Cell sub-journal interpretation! Uncover the hot tissue areas where SARS-CoV-2 causes infections in human bodies!
Time of Update: 2020-10-06
!--, September 23, 2020 // -- In a recent study published in the international journal Cell Reports entitled "A single-cell RNA expression map of human coronavirus entry factors", scientists from Corn
-
Biochem Pharmacol: Experimental drugs have the potential to treat new coronavirus infections.
Time of Update: 2020-10-06
the team must develop a clinical trial plan and obtain FDA approval to test AR-12 on COVID-19 patients and manufacture enough drugs to be tested.
-
Chinese scientists have revealed key kinases that regulate T-cell failure.
Time of Update: 2020-10-06
by further detecting the correlation between MAP4K1 and other inhibitory ligenes in tumor-invasive T-cells, MAP4K1 was positively related to T-cell failure signals (CD3E, TIGIT, PDCD1, CTLA4, HAVCR2, and LAG3) in different cancer patients, and HPK1 expression in inhibited and HPK1 proteins in tumor specimens was also found to be increased.
